| Type: | combo |
| Component1: | Atezolizumab |
| Class1: | Monoclonal antibody |
| Component2: | Hyaluronidase |
| Class2: | Endoglycosidase |
| Tradename: | Tecentriq Hybreza |
| Dailymedid: | Atezolizumab and hyaluronidase |
| Routes Of Administration: | Subcutaneous |
| Atc Prefix: | None |
| Legal Us: | Rx-only |
Atezolizumab/hyaluronidase, sold under the brand name Tecentriq Hybreza, is a fixed-dose combination medication used for the treatment of non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part sarcoma. It contains atezolizumab, a programmed death-ligand 1 (PD-L1) blocking monoclonal antibody; and hyaluronidase (human recombinant), an endoglycosidase. It is taken by subcutaneous injection.[1]
The most common adverse reactions include fatigue, musculoskeletal pain, cough, dyspnea, and decreased appetite.
Atezolizumab/hyaluronidase was approved for medical use in the United States in September 2024.[2] [3] [4]
Atezolizumab/hyaluronidase is a subcutaneous injection version of atezolizumab for all the adult indications as the intravenous formulation of atezolizumab including non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part sarcoma.
The subcutaneous injection of atezolizumab and hyaluronidase was evaluated in IMscin001 (NCT03735121), an open-label, multi-center, international, randomized trial in adults with locally advanced or metastatic non-small cell lung cancer who were not previously exposed to cancer immunotherapy and who had disease progression following treatment with platinum-based chemotherapy. A total of 371 participants were randomized (2:1) to receive subcutaneous atezolizumab and hyaluronidase or intravenous atezolizumab until disease progression or unacceptable toxicity.